|
AU2014200030A1
|
|
Pyrimidine Derivatives Useful as Raf Kinase Inhibitors
|
|
AU2013203964A1
|
|
Boronate ester compounds and pharmaceutical compositions thereof
|
|
AU2013203433A1
|
|
Heteroaryl compounds useful as inhibitors of E1 activating enzymes
|
|
MX2013001660A
|
|
Heteroaryls and uses thereof.
|
|
WO2012012320A1
|
|
Substituted hydroxamic acids and uses thereof
|
|
CA2765678A1
|
|
Substituted hydroxamic acids and uses thereof
|
|
MX343391B
|
|
Compounds for inhibiting mitotic progression.
|
|
US7442830B1
|
|
Proteasome inhibitors
|
|
US2007037972A1
|
|
Method of acylating maytansinol with chiral amino acids
|
|
US2005266420A1
|
|
Multigene predictors of response to chemotherapy
|
|
US7771953B2
|
|
Methods of diagnosing and treating cancer
|
|
AU2003276877A1
|
|
Crystal structure of angiotensin-converting enzyme-related carboxypeptidase
|
|
AU2003243318A1
|
|
Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
|
|
EP1336619A2
|
|
Combination of a HVEM-LIGHT inhibitor and an immunosuppressive agent in the treatment or prevention of immune disorders
|
|
US2003113787A1
|
|
Molecules of the card-related protein family and uses thereof
|
|
EA008060B1
|
|
Chemokine receptor antagonists and methods of use thereof
|
|
EP1326076A2
|
|
Methods for indentification of ligands or modulators of 2871 receptor, a g-protein coupled receptor
|
|
WO03044160A2
|
|
Novel molecules of the card related protein family and uses thereof
|
|
AU2002364891A1
|
|
Novel molecules of the card related protein family and uses thereof
|
|
WO03004067A1
|
|
Methods and compositions for the treatment and diagnosis of body weight disorders
|
